· RabbitsEMEA/CVMP · Validation · Opinion · Active time · Clock stop · 15.11.2001 · 13.2.2002 · 90 days ·0 · 17.1.2002 · 17.4.2002 · 90 days ·0 · 6.9.2001 · 17.4.2002 · 114 days · 109 days · 17.1.2002 · 17.4.2002 · 90 days ·0 · 13.7.2001 · 15.5.2002 · 87 days · 219 days · 12.4.2001 · 12.6.2002 · 120 days · 306 days · 9.8.2001 · 12.6.2002 · 120 days · 187 days · 11.4.2002 · 10.7.2002 · 90 days ·0 · 16.8.2002 · 13.11.2002 · 86 days ·0European Commission · Opinion received · Date of regulation · Official Journal· 11.3.2002 · 27.8.2002 · OJ L 230, 28.8.2002· 13.5.2002 · 1.10.2002 · OJ L 264, 2.10.2002· 13.5.2002 · 1.10.2002 · OJ L 264, 2.10.2002· 13.5.2002 · 1.10.2002 · OJ L 264, 2.10.2002· 13.6.2002 · 30.10.2002 · OJ L 297, 31.10.2002· 12.7.2002 · 30.10.2002 · OJ L 297, 31.10.2002· 12.7.2002 · 30.10.2002 · OJ L 297, 31.10.2002· 1.8.2002 · ·· · ·EMEA Annual Report 200257COMP opinions in 2002 on designation of orphan medicinal productsPositive COMP designation opinionsProduct INN· 4-(3,5-Bis(hdroxy-phenyl) -1,2,4) triazol-1-yl) benzoic acid (ICL670)· Beclomethasone 17, 21-dipropionate· Nitisinone· GM-CSF receptor antagonist· Human transferrin conjugated to mutant diptheria toxin· Chimeric IgG monoclonal antibody cG250 for use with 131Iodine· Chimeric IgG monoclonal antibody cG250· TGF-ß2-specific phosphorothioate antisense oligodeoxynucleotide (Oncomun) · Humanized anti-KSA monoclonal antibody -human interleukin-2-fusion protein (EMD 273066) · Epothilone B (EPO 906 A)58 EMEA Annual Report 2002Sponsor· Novartis Europharm Limited· Voisin Consulting SARL

Swedish Orphan International ABBritish Biotech Pharmaceuticals Ltd -KS Biomedix Holdings PLCWilex AGWilex AGAntisense Pharma GmbHMerck KGaANovartis Europharm LimitedPPD Global Ltd.PromotorGPC Biotech AGBaxter AGHemeBiotech A/SZentaris AGLaboratoire HRA PharmaBoehringer Ingelheim International GmbHSciClone Pharmaceuticals Italy S. r. l.InDex Pharmaceuticals ABDorian Regulatory AffairsAdprotech Ltd.Prof.Keith JudkinsEthicare GmbHResumo da indicaçãoTreatment of chronic iron overload requiring chelation therapy